PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20877134-0	2010	Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro.	diosmetin	11-20	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-80	
29710546-0	2018	Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin.	diosmetin	31-40	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93	
29710546-5	2018	In this study, the inhibitory action of DIO and SIL on CYP2C9-catalyzed metabolism of diclofenac to 4"-hydroxydiclofenac was examined, using warfarin as a positive control.	diosmetin	40-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	55-61	
29710546-7	2018	It is demonstrated that DIO and SIL are potent inhibitors of CYP2C9 enzyme and are able to displace the Site I ligand warfarin from human serum albumin.	diosmetin	24-27	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67	
20877134-1	2010	The aim of this study was to examine in vitro, by means of kinetic analysis and molecular docking simulations, the effects of the flavone diosmetin and its flavanone analog hesperetin on CYP (cytochrome P450) 2C9-mediated drug metabolism.	diosmetin	138-147	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	192-212	
20877134-6	2010	The results of molecular docking simulations were consistent with those of kinetic analysis, since they showed that the putative binding sites of both diosmetin and hesperetin coincided with the CYP2C9 substrate binding site.	diosmetin	151-160	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	195-201	
20877134-7	2010	The demonstration that diosmetin and hesperetin inhibit CYP2C9-mediated diclofenac metabolism at low micromolar concentrations is of potential clinical relevance because CYP2C9 is responsible for the biotransformation of various therapeutically important drugs that have narrow therapeutic indexes.	diosmetin	23-32	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	56-62	
20877134-7	2010	The demonstration that diosmetin and hesperetin inhibit CYP2C9-mediated diclofenac metabolism at low micromolar concentrations is of potential clinical relevance because CYP2C9 is responsible for the biotransformation of various therapeutically important drugs that have narrow therapeutic indexes.	diosmetin	23-32	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	170-176